Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($)							1 Months Ended		3 Months Ended		6 Months Ended
Liquidity (Details Narrative) - USD ($)	Jun. 21, 2017	Jun. 16, 2017	Apr. 18, 2017	Feb. 08, 2017	Jan. 25, 2017	Jan. 06, 2017	Apr. 18, 2017	Dec. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 22, 2017	Sep. 28, 2016	Jun. 21, 2016	Dec. 31, 2015	Oct. 31, 2014
Cash and cash equivalents								$ 602,000	$ 14,265,000	$ 3,039,000	$ 14,265,000	$ 3,039,000				$ 8,310,000
Accounts receivable, net								2,209,000	2,696,000		2,696,000
Total current assets								4,240,000	18,337,000		18,337,000
Total current liabilities								16,241,000	10,855,000		10,855,000
Net income (loss)									$ (6,306,000)	$ (2,334,000)	(3,892,000)	(7,120,000)
Net cash used in operating activities											8,675,000	5,271,000
Proceeds from issuance of sale of equity											25,900,000
Number of common stock shares issued	9,900,000
Gross proceeds from equity offerings											25,900,000
Debt conversion, converted instrument, amount											$ 8,869,000
Debt conversion, converted instrument, shares issued							3,795,429
Underwriters over-allotment option to purchase common stock		1,875,000
SCM Specialty Finance Opportunities Fund, L.P [Member]
Line of credit														$ 1,200,000
July 7, 2017 [Member]
Warrant exercise price									$ 0.01		$ 0.01
July 31, 2017 [Member]
Warrant exercise price									0.19		$ 0.19
Gross proceeds from equity offerings											$ 960,000
Underwriters over-allotment option to purchase common stock											875,000
Base Warrants [Member]
Number of common stock shares issued	12,500,000
Common stock issued price per share	$ 1.10
Warrants description	Each Base Warrant upon exercise at a price of $1.25 will result in the issuance of one share of common stock to the holder. A public trading market for the Base Warrants was established on July 5, 2017 on the OTC market under the trading symbol IDGGW.
Warrant exercise price	$ 0.01
Gross proceeds from equity offerings	$ 13,700,000
Underwriters over-allotment option to purchase common stock		1,875,000
Prefunded Warrants [Member]
Number of common stock shares issued	2,600,000
Warrant to purchase shares of common stock	2,600,000	2,600,000
Warrant exercise price		$ 1.09							$ 0.01		$ 0.01
Gross proceeds from equity offerings	$ 12,300,000
Prefunded Warrants [Member] \| July 7, 2017 [Member]
Warrant to purchase shares of common stock									2,600,000		2,600,000
Underwriter Warrants[Member]
Number of common stock shares issued	575,000
Warrant to purchase shares of common stock	575,000														1,875,000
Warrant exercise price									$ 1.32		$ 1.32
Exchanged Convertible Note and the Senior Secured Convertible Note [Member]
Debt instrument, face amount													$ 3,550,000
Senior Secured Convertible Note [Member]
Debt conversion, converted instrument, shares issued							3,795,429
RedPath Note [Member]
Debt instrument, face amount								9,340,000									$ 1,070,000
Repayments of debt								$ 1,330,000
RedPath Note [Member] \| Senior Secured Non-Convertible Note [Member]
Debt instrument, face amount			$ 3,550,000				$ 3,550,000		$ 3,550,000		$ 3,550,000		5,320,000
Debt conversion, converted instrument, amount			$ 3,550,000
Debt conversion, converted instrument, shares issued			3,795,429
RedPath Note [Member] \| Senior Secured Convertible Note [Member]
Debt instrument, face amount									$ 5,320,000		$ 5,320,000
RedPath Note [Member] \| Investor [Member]
Debt instrument, face amount													$ 8,870,000
Second Registered Direct Offering [Member]
Proceeds from issuance of sale of equity						$ 4,200,000
Number of common stock shares issued						630,000
Common stock issued price per share						$ 6.81
Third Registered Direct Offering [Member]
Number of common stock shares issued					855,000
Common stock issued price per share					$ 4.69
Warrant to purchase shares of common stock					855,000
Third Registered Direct Offering and Private Placement [Member]
Proceeds from issuance of sale of equity					$ 4,000,000
Settlement of obligation					$ 1,000,000
Confidentially Marketed Public Offering [Member]
Proceeds from issuance of sale of equity				$ 3,900,000
Number of common stock shares issued				1,200,000
Common stock issued price per share				$ 3.00
Percentage of additional option granted for underwriters				9.00%